Self‐Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Per‐Glycosylated MUC1 Glycopeptides and the Toll‐like Receptor 2 Agonist Pam3CysSer

More sugar with your “T”: The title candidates comprising per-glycosylated MUC1 peptides, a T-cell helper peptide, and an immunoadjuvant were assembled in high yields using iterative pentafluorophenyl ester-mediated fragment condensations. Following immunological evaluation, a tricomponent vaccine bearing clustered glycosylation with the T-antigen was identified (see structure) which elicited high IgG antibody titers in murine models without an external adjuvant. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.